TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8672317
Drug: Digital pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital pressure applied 6-8 cm below the neurovascular sheath during injection of 2% mepivacaine with adrenaline (20 ml) mixed with contrast agent (20 ml).
Study: 2088996
Drug: 30‐mg controlled‐release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30‐mg controlled‐release morphine tablet (MS Contin Tablet) after a high fat meal
Study: 2088996
Drug: 30‐mg controlled‐release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30‐mg controlled‐release morphine tablet (MS Contin Tablet) after fasting
Study: 28738490
Drug: Ultrafiltration therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrafiltration therapy for 8 hours
Study: 1932608
Drug: Combination tablet
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination tablet of enalapril (10 mg) and hydrochlorothiazide (25 mg)
Study: 1932608
Drug: Enalapril tablet
Normalized name: enalapril Oral Tablet
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril tablet (10 mg)
Study: 1932608
Drug: Hydrochlorothiazide tablet
Normalized name: Hydrochlorothiazide Tablets
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide tablet (25 mg)
Study: 1932608
Drug: Simultaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous administration of separate tablets of enalapril (10 mg) and hydrochlorothiazide (25 mg)
Study: 7015537
Drug: Oxprenolol HCl
Normalized name: oxprenolol HCl
DrugBank: Oxprenolol (DB01580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxprenolol HCl 160 mg slow-release plus cyclopenthiazide 0.25 mg and potassium chloride 600 mg
Study: 30025819
Drug: HER2-peptide vaccines
Normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HER2-peptide vaccines
Study: 27514617
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg prasugrel
Study: 16144987
Drug: Valsartan (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (160 mg/d) administered on awakening
Study: 7489584
Drug: Aktiferrin capsules
Normalized name: Yttrium (90Y) Antiferritin Polyclonal Antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aktiferrin capsules
Study: 6896406
Drug: Allopurinol (xanthine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (xanthine oxidase inhibitor)
Study: 29145788
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Therapy (CPT) delivered via videoconferencing
Study: 29145788
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Therapy (CPT) delivered in-person
Study: 29555631
Drug: Rezafungin (CD101)
Normalized name: Rezafungin
DrugBank: Rezafungin (DB16310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rezafungin (CD101) administered intravenously
Study: 24159790
Drug: Cycloferon (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycloferon (7.5 g) combined with antibacterial therapy
Study: 20735821
Drug: Triple anti-platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple anti-platelet therapy (cilostazol, aspirin, clopidogrel)
Study: 20735821
Drug: Dual anti-platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual anti-platelet therapy (aspirin and clopidogrel)
Study: 20735821
Drug: Triple anti-platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple anti-platelet therapy
Study: 20735821
Drug: Dual anti-platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual anti-platelet therapy
Study: 18426639
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg folic acid daily
Study: 10481354
Drug: Tele-medicine system
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tele-medicine system for asthma management
Study: 27717222
Drug: Exenatide once-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide once-weekly (subcutaneous injections)
Study: 22028071
Drug: 20 µg of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 µg of HyD per day
Study: 22028071
Drug: 20 µg (800 IU)
Normalized name: hyaluronidase
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 µg (800 IU) of vitamin D(3) per day
Study: 9711797
Drug: 10 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micrograms of recombinant hepatitis B vaccine (GenHevac B) intramuscularly (i.m.)
Study: 9711797
Drug: 2 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 micrograms of recombinant hepatitis B vaccine (GenHevac B) intradermally (ID)
Study: 7974084
Drug: Cobalt-60 therapy
Normalized name: Cobalt
DrugBank: Cobalt (DB14574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cobalt-60 therapy followed by hormonotherapy after progression
Study: 31912784
Drug: Graded Exercise
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded Exercise Therapy (GET) for 12 weeks
Study: 23957590
Drug: Probiotic mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic mixture (Lactobacillus paracasei ssp paracasei F19, Lactobacillus acidophilus La5, Bifidobacterium Bb12) 1.3 × 10(10) CFU per capsule, two capsules twice daily for 6 months
Study: 23957590
Drug: Placebo, two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, two capsules twice daily for 6 months
Study: 21834970
Drug: Enhanced pharmacist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced pharmacist care (patient identification, assessment, education, close follow‐up, and prescribing/titration of antihypertensive medications)
Study: 22500389
Drug: Modified Shenqi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Shenqi Dihuang Decoction (MSDD) plus basic treatment of Western medicine
Study: 22500389
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment of Western medicine alone
Study: 17290328
Drug: Targeted therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted therapies (tyrosine kinase and angiogenesis inhibitors)
Study: 9172168
Drug: Increased risk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased risk for NIDDM (defined by higher 2 h glucose and insulin values on oral glucose tolerance testing)
Study: 8385741
Drug: Sulindac (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac (150 mg orally twice a day for nine months)
Study: 3957482
Drug: Oral terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbutaline (5 mg three times daily for two weeks)
Study: 22364383
Drug: Percutaneous coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary intervention with drug-eluting stent (DES-PCI)
Study: 15882173
Drug: Preoperative combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative combined chemoradiation (external‐beam radiotherapy to 45 Gy plus weekly cisplatin 50 mg/m2)
Study: 15882173
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NAIC) (cisplatin 50 mg/m2 and vincristin 1 mg/m2 every 7‐10 days for three courses)
Study: 14624765
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) treatment (Genotropin, Pharmacia Corporation) for 6 months
Study: 6283422
Drug: Amitriptyline (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (75 mg median dose)
Study: 27652610
Drug: Standard prasugrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard prasugrel therapy (control group)
Study: 27652610
Drug: De-escalating therapy
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: De-escalating therapy (one-week prasugrel followed by one-week clopidogrel and PFT-guided maintenance therapy)
Study: 29127842
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (0.5mg/day)
Study: 12357162
Drug: Intrathecal adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal adenosine 0.5 mg
Study: 12357162
Drug: Intrathecal adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal adenosine 2.0 mg
Study: 14557958
Drug: 7-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine (PncOMPC)
Study: 9578008
Drug: High-dose barbiturates
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose barbiturates
Study: 7644238
Drug: Intramuscular ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ketorolac (1 mg/kg)
Study: 2526633
Drug: Recombinant hepatitis
Normalized name: Recombinant hepatitis B human immunoglobulin
DrugBank: Lenvervimab (DB17814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant hepatitis B vaccine (HBVax II, MSD, 5 micrograms)
Study: 2526633
Drug: Plasma derived
Normalized name: c1-inhibitor, plasma derived
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma derived hepatitis B vaccine (HBVax, MSD, 10 micrograms)
Study: 136668
Drug: Mianserin hydrochloride
Normalized name: Mianserin hydrochloride
DrugBank: Mianserin (DB06148)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin hydrochloride (20 mg three times daily)
Study: 22702846
Drug: Combination etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Combination etanercept and NB-UVB phototherapy
Study: 22702846
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (etanercept monotherapy and combination therapy)
Study: 21785174
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) and erythropoietin (EPO) based intracoronary infusion of peripheral blood stem cells (PBSCs) after 5 days of G-CSF administration and EPO at the time of PBSCs injection
Study: 19111789
Drug: Effective surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effective surgical treatment costing $40,000
Study: 16458799
Drug: Self‐reinforced poly‐L‐lactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self‐reinforced poly‐L‐lactic acid polymer (PLLA group, n = 20)
Study: 11783366
Drug: GnRH‐a long
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH‐a long protocol (0.9 mg/day nasal spray starting on day 21)
Study: 11783366
Drug: GnRH‐a short
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH‐a short protocol (0.45 mg/day nasal spray starting on day 2)
Study: 30153359
Drug: Simtuzumab 75
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Simtuzumab 75 mg
Study: 30153359
Drug: Simtuzumab 125
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Simtuzumab 125 mg
Study: 30153359
Drug: Simtuzumab 75
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Simtuzumab 75 mg and 125 mg
Study: 28060063
Drug: 1.2 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g/d of a triglyceride formulation of oral omega-3 fatty acids for 12 weeks
Study: 28060063
Drug: 400 mg/d
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/d vitamin E for 12 weeks
Study: 26209038
Drug: Glimepiride (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (1 mg/day) - Control
Study: 21140383
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg of EGb 761 once daily for 24 weeks
Study: 11449954
Drug: Solvent/detergent-treated intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solvent/detergent-treated intramuscular immunoglobulin
Study: 11449954
Drug: Standard intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intramuscular immunoglobulin
Study: 9610964
Drug: Intravenous propafenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous propafenone (2 mg/kg for 10 min)
Study: 3260083
Drug: 0.05 mg
Normalized name: biotin 0.05 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg propofol/kg per minute
Study: 3260083
Drug: 0.10 mg
Normalized name: povidone-iodine 0.10 mg in 1 mL TOPICAL SOLUTION [Povidone Iodine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.10 mg propofol/kg per minute
Study: 3260083
Drug: 0.15 mg
Normalized name: iodine 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg propofol/kg per minute
Study: 3260083
Drug: 0.20 mg
Normalized name: FENTANYL 10.20 mg in 1 [USP'U] TRANSDERMAL PATCH [Fentanyl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.20 mg propofol/kg per minute
Study: 26333513
Drug: Plant sterols
Normalized name: Plant Sterols/Stanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterols (2 g PS/d)
Study: 18178379
Drug: Supplemented hypokinetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemented hypokinetic subjects (SHKSs) with daily supplementation of 0.7 mmol of calcium lactate per kilogram of body weight
Study: 16813479
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of isotonic exercises
Study: 12708129
Drug: Oral medication
Normalized name: Oral Medication Syringe 3mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral medication (Group I)
Study: 12708129
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment (Group II)
Study: 8621989
Drug: Propranolol with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol with aspirin and/or coronary artery surgery
Study: 8621989
Drug: Propranolol without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol without aspirin and/or coronary artery surgery
Study: 17548693
Drug: Serum alpha‐tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum alpha‐tocopherol supplementation (50 mg daily for 5‐8 years)
Study: 15233282
Drug: Disopyramide (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disopyramide (6 mg/kg)
Study: 15233282
Drug: Mexiletine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine (4 mg/kg)
Study: 15233282
Drug: Pilsicainide (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilsicainide (4 mg/kg)
Study: 9203234
Drug: Risperidone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (mean dose at endpoint: 5.9 mg/day)
Study: 11767424
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of physiological saline injection (Group A)
Study: 11767424
Drug: No injection
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No injection (Group B)
Study: 20570240
Drug: Subconjunctival injection
Normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival injection of 0.02% MMC 1 month before bare scleral excision
Study: 18812325
Drug: Isoflavone supplement
Normalized name: Soyrel Soy Isoflavone Supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone supplement (80 mg/day)
Study: 16911386
Drug: 1% topical
Normalized name: SSD 1% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% topical methotrexate gel
Study: 16911386
Drug: Placebo (vaseline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vaseline ointment)
Study: 12816908
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg THC/day)
Study: 11053334
Drug: Caffeine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (6 mg/kg) and Theophylline (4.5 mg/kg)
Study: 6381186
Drug: 4-amino-salicylic acid
Normalized name: para-amino salicylic acid
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-amino-salicylic acid (4-ASA) enemas (1 g)
Study: 6381186
Drug: 4-amino-salicylic acid
Normalized name: para-amino salicylic acid
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-amino-salicylic acid (4-ASA) enemas (2 g)
Study: 31390900
Drug: Stress management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stress management program (weekly group-based sessions over an 8-week period)
Study: 21510527
Drug: Injection clonidine
Normalized name: clonidine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection clonidine 150 mcg
Study: 21510527
Drug: Injection midazolam
Normalized name: midazolam Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection midazolam 5 mg
Study: 2246712
Drug: HCl supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCl supplementation (0.01-0.02 ml of 1 N HCl/ml of milk)
Study: 6352793
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous treatment
Study: 6352793
Drug: Traditional intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional intensive insulin therapy
Study: 31248268
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (new users)
Study: 23129559
Drug: Mindfulness‐based Art
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness‐based Art Therapy (MBAT)
Study: 20558922
Drug: Miglitol 75
Normalized name: Miglitol
DrugBank: Miglitol (DB00491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Miglitol 75 mg per meal
Study: 20558922
Drug: Acarbose 100
Normalized name: acarbose 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose 100 mg per meal
Study: 18259090
Drug: aspirin +
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: aspirin + propranolol
Study: 16973686
Drug: Strict rate
Normalized name: Euphrasia stricta extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strict rate control (AFFIRM) aiming for resting heart rate <=80 bpm and heart rate during daily activity <=110 bpm
Study: 6241559
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptives (30 micrograms ethinyl estradiol and 150 micrograms levonorgestrel)
Study: 6241559
Drug: Progestin-only preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestin-only preparation (75 micrograms dl-norgestrel)
Study: 31713723
Drug: Ubiquinol 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ubiquinol 400 mg/day for 3 months
Study: 25054775
Drug: 2-month prednisolone
Normalized name: prednisolone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-month prednisolone treatment
Study: 25054775
Drug: 6-month prednisolone
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month prednisolone treatment
Study: 23421353
Drug: GHB (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHB (1, 2, 4, 6, 8, and 10 g/70 kg)
Study: 23421353
Drug: Ethanol (12,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (12, 24, 48, 72, 96, and 120 g/70 kg)
Study: 23421353
Drug: GHB and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHB and Ethanol (highest tolerated doses)
Study: 16877376
Drug: SQ regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ regimen (half of the FSH dose required for follicular development)
Study: 12826993
Drug: SSRI (sertraline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRI (sertraline)
Study: 12826993
Drug: Tricyclic antidepressant
Normalized name: Tricyclic antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricyclic antidepressant (nortriptyline)
Study: 8862104
Drug: Metered dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered dose inhaler (MDI)
Study: 8862104
Drug: Self-administration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administration of salbutamol by MDI
Study: 8862104
Drug: MDI therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI therapy with supervision
Study: 1623994
Drug: 4.0-cm contraceptive
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0-cm contraceptive implant
Study: 1623994
Drug: 2.5-cm contraceptive
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5-cm contraceptive implant
Study: 6435371
Drug: Insulin and
Normalized name: Isophane insulin and porcine regular insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin and glibenclamide treatment
Study: 28231835
Drug: Vildagliptin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin (100 mg/day)
Study: 28231835
Drug: Glibenclamide (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (2.5 mg bid to a maximal dose of 5 mg bid)
Study: 24383441
Drug: Computer tablet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer tablet-based prenatal psychosocial assessment (e-screening)
Study: 9250800
Drug: Early G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early G-CSF (filgrastim 5 microg/kg/d) from day 4 of IVAP
Study: 9250800
Drug: Late G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late G-CSF (filgrastim 5 microg/kg/d) from day 15 of IVAP
Study: 8342211
Drug: Experiential suicide
Normalized name: modified Ankara virus-mediated suicide gene delivery vector TG4023
DrugBank: TG4023 (DB06108)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experiential suicide prevention program (7 weekly 2-hour meetings)
Study: 3783203
Drug: Chemoendocrine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoendocrine therapy with cyclophosphamide, methotrexate, 5‐fluorouracil, low‐dose continuous prednisone, and tamoxifen (CMFp + T) for 12 months
Study: 3783203
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy alone with prednisone and tamoxifen (p + T) for 1 year
Study: 3783203
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant treatment after mastectomy (observation)